| Literature DB >> 35602412 |
Yijing Wang1,2, Junko Tanuma3, Jinghua Li1, Kota Iwahashi4, Liping Peng1, Chun Chen5,6, Yuantao Hao1,7,8, Stuart Gilmour2.
Abstract
Background: Japan has a concentrated HIV epidemic, with the majority of transmission among men who have sex with men (MSM). This study aimed to explore the effect of behavioral and biomedical interventions on the HIV epidemic and forecast the time required to eliminate HIV transmission among Japanese MSM.Entities:
Keywords: HIV infections; Incidence; Interventions; Japan; Mathematical models; Policy
Year: 2022 PMID: 35602412 PMCID: PMC9118161 DOI: 10.1016/j.lanwpc.2022.100467
Source DB: PubMed Journal: Lancet Reg Health West Pac ISSN: 2666-6065
Figure 1Compartmental structure of the model.
Model parameters
| Parameter | Value | References |
|---|---|---|
| Initial population (age 18-59) | ||
| Men | 35763734 | |
| MSM (%) | 3.5 | |
| Low-risk MSM (%) | 80 | |
| High-risk MSM (%) | 20 | |
| Background maturation and entry rates | ||
| Annual maturation rate, male | 0.0271 | Calculateda |
| Annual entry rate, male | 0.0167 | Calculatedb |
| Background mortality rate | ||
| Annual mortality rate, male | 0.00486 | |
| Annual mortality rate without ART | ||
| Acute | 0.003 | |
| Asymptomatic (CD>500) | 0.03 | |
| Asymptomatic (200<=CD4<=500) | 0.1 | |
| AIDS (CD4<200) | 0.48 | |
| Annual mortality rate with ART | ||
| Acute | 0.002 | |
| Asymptomatic (CD>500) | 0.002 | |
| Asymptomatic (200<=CD4<=500) | 0.01 | |
| AIDS (CD4<200) | 0.02 | |
| Duration of HIV progression status converted to months* | ||
| Acute to CD4>500 | 3 | |
| CD4>500 to 200<=CD4<=500 | 14.3 | |
| 200<=CD4<=500 to CD4<200 | 80.33 | |
| Probability of HIV transmission per partnership | ||
| Acute (within 3 months) | 0.21 | |
| Asymptomatic (CD>500) | 0.003 | |
| Asymptomatic (200<=CD4<=500) | 0.045 | |
| AIDS (CD4<200) | 0.12 | |
| Reduction in infectivity (multiplicative) due to ART | 0.99 | |
| Annual number of partners | ||
| MSM, total | 4.1 | |
| Low risk MSM | 1.6 | Calculatedc |
| High risk MSM | 14.1 | |
| Condom use (% of sexual encounters) | ||
| Condom use rate (%) | 35% | |
| Condom effectiveness | 0.9 | |
| Others | ||
| Proportion of members of one group having sexual interaction with members of the other group | 0.3 | Assumed |
| Reduction in sexual behavior after HIV diagnosis | 0.2 | Assumed |
| Reduction in sexual behavior among AIDS patients | 0.9 | Assumed |
| HIV testing rate | ||
| Proportion of population tested in past 12 months, % | 35% | |
| Rate of detection of HIV through passive case-finding | 0.1 | Assumed |
| Rate of detection of AIDS through passive case-finding | 1 | Assumed |
| Average duration that uninfected individuals remain identified after testing in risk | 12 months | |
| Monthly entry rate to ART (treatment rate) | ||
| Acute | 0.2 | Calculatedd |
| Asymptomatic (CD>500) | 0.29 | Calculatedd |
| Asymptomatic (200<=CD4<=500) | 0.38 | Calculatedd |
| AIDS (CD4<200) | 0.43 | Calculatedd |
| Pre-exposure prophylaxis | ||
| Rate of uninfected people start taking PrEP | - | Based on the scenarios |
| Rate of PrEP dropout | 0 | 100% adherence |
| PrEP Effectiveness | 0.9 under 100% adherence | |
| Transmission forcee (k=1,2 means not in PrEP, k=3 means in PrEP) | - |
NOTE: *Duration doubled after ART. Calculateda: The rate of aging. Calculatedb: The rate of entering the 18-59 age group. Calculatedc: Annual number of partners in LRMSM was calculated coordinated with the proportion of people in each group and the annual number of partners in HRMSM to ensure the annual number of partners of 4.1 in the whole population. Calculatedd: Obtained using survival analysis of the data obtained from the clinic cohort at AIDS Clinical Center. Transmission forcee: Transmission force represents the rate of uninfected people entering the infected population, which is the sum of force of infections with each infectious compartment. The detailed calculations are shown in Supplementary Section 1.2 and 1.3.
Figure 2HIV prevalence (A) and HIV incidence rate (B) under status quo of current policies and three kinds of comprehensive behavior and biomedical interventions.
Figure 3R (A) and the time required to eliminate HIV (B) under partner reduction intervention. (The blank for values above 9 in the right panel indicates failure to achieve HIV elimination within 28 years (i.e., by 2050)).R (C) and the time required to eliminate HIV (D) under increased condom use intervention. (The blank for values below 65% in the right panel indicates failure to achieve HIV elimination within 28 years).R (E) and the time required to eliminate HIV (F) under behavioral combination intervention. (The numbers on the curves represent the value of
Figure 4(The numbers on the curves represent the value of R in the left panel and the time required to eliminate HIV in the right panel at the testing rate and treatment rate corresponding to any point on the curve). (The numbers on the curves represent the value of R in the left panel and the time required to eliminate HIV in the right panel at the testing and treatment rate and PrEP coverage rate corresponding to any points on the curves).
Years of elimination of HIV transmission under different intervention scenarios.
| Intensity | Intervention | Year of elimination of HIV transmission | ||||||
|---|---|---|---|---|---|---|---|---|
| Scenario 1 (Sensitivity range) | Scenario 2 (Sensitivity range) | Scenario 3 (Sensitivity range) | Scenario 4 (Sensitivity range) | Scenario 5 (Sensitivity range) | Scenario 6 (Sensitivity range) | Comprehensive interventions (Sensitivity range) | ||
| Weak | Partner reduction: 10% | After 2050 | After 2050 | 2032 (2031 – 2033) | ||||
| Condom use rate: 40% | After 2050 | |||||||
| Testing and treatment: 50% | After 2050 | 2038 (2036 -2039) | ||||||
| PrEP coverage rate: 10% | 2047 (2046 –2049) | |||||||
| Moderate | Partner reduction: 20% | After 2050 | 2037 (2031-2043) | 2025 (2024 – 2026) | ||||
| Condom use rate: 50% | After 2050 | |||||||
| Testing and treatment: 70% | After 2050 | 2030 (2029 – 2031) | ||||||
| PrEP coverage rate: 20% | 2040 (2038 – 2041) | |||||||
| Strong | Partner reduction:30% | After 2050 | 2030 (2026 -2032) | 2024 (2023 – 2024) | ||||
| Condom use rate: 60% | After 2050 | |||||||
| Testing and treatment: 90% | 2034 (2030 – 2037) | 2027 (2026 – 2028) | ||||||
| PrEP coverage rate: 30% | 2036 (2034 –2037) | |||||||
HIV epidemic forecast under different intervention scenarios.
| Status quo | Weak intervention | Moderate intervention | Strong intervention | |
|---|---|---|---|---|
| Epidemiological impact | ||||
| Prevalence in 2050 (%) | 9.70 (8.93, 10.43) | 2.25 (1.62, 2.83) | 1.38 (0.99, 1.79) | 1.22 (0.88, 1.57) |
| Incidence rate in 2050 (/1000 person-year) | 3.00 (2.50, 4.10) | 0.046 (0.033, 0.058) | 0.0053 (0.0033, 0.0072) | 0.0020 (0.0013, 0.0027) |
| Total HIV infections from 2022 to 2050 (× 10,000) | 16.17 (11.22, 20.78) | 3.04 (1.97, 4.05) | 0.91 (0.53, 1.30) | 0.41 (0.24, 0.60) |
| HIV infections prevented from 2022 to 2050 (× 10,000) | - | 13.13 (9.08, 16.87) | 15.26 (10.67, 19.49) | 15.76 (10.98, 20.19) |
| HIV infections prevented from 2022 to 2050 (%) | - | 81.23 (75.45, 90.17) | 94.41 (92.22, 97.53) | 97.48 (96.45, 98.92) |
| Required number of tests/treatments/people taking PrEP in the first year of the intervention (i.e., 2022) | ||||
| Number of tests required (× 100,000) | - | 3.22 (3.03, 3.44) | 4.17 (3.92, 4.46) | 4.96 (4.67, 5.30) |
| Number of treatments required (× 1000) | - | 3.16 (1.76, 4.63) | 4.47 (2.48, 6.58) | 5.68 (3.15, 8.40) |
| Number of PrEP required (× 10,000) | 0 | 2.57 (2.44, 2.73) | 5.79 (5.50, 6.13) | 9.48 (8.99, 10.02) |